Amgen AMGN TAVNEOS — Finite-lived intangible assets, gross
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amgen's tavneos — finite-lived intangible assets, gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amgen's TAVNEOS — finite-lived intangible assets, gross?
- Amgen (AMGN) reported TAVNEOS — finite-lived intangible assets, gross of $2.4B in Q1 2026.
- What does TAVNEOS — finite-lived intangible assets, gross mean?
- The total original cost of acquired product rights and intellectual property for the TAVNEOS therapeutic line.
- How do you interpret TAVNEOS — finite-lived intangible assets, gross?
- An increase indicates recent acquisitions or capital investments in product rights, while a decrease reflects the impairment or write-off of these assets. High gross values relative to revenue may suggest significant upfront investment in external innovation.
- How does TAVNEOS — finite-lived intangible assets, gross compare across companies?
- Comparable to 'Acquired Product Rights' or 'Intangible Assets' reported by other biotechnology firms following M&A activity or licensing deals.